Patients with non-small cell lung cancer and the AA genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.